Trabeculectomy Surgery
Conditions
Interventions
Data is extracted from medical charts (background history, glaucoma characteristics, baseline IOP, preoperative visual acuity, number of ocular hypotensive medication, safety parameters, follow-up fro
at months 3, 6, 12 and 24 after trabeculectomy, number of postoperative IOP-lowering medication and surgical interventions). All consecutive patients from one site (Centro Hospitalar Universitário Lis
all consecutive patients from the second site (Hospital dos Lusíadas) received the becavizumab as an add on to standard of care. Statistical analysis is carried out using SPSS software (Chicago, IL, v
Sponsors
Centro Hospitalar Lisboa Norte
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients submitted to primary trabeculectomy for open-angle glaucoma between October 2015 and March 2019 2. No other previous surgeries, except uncomplicated phaco 3. = 18 years and have agreed to chart review as per GDPR regulations
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breastfeeding 2. Combination with cataract surgery 3. History of another eye disease 4. Uncontrolled blood pressure (systolic >180 mmHg and/or diastolic >100 mmHg while a patient is at rest) 5. Severe cardiovascular disease (including a stroke or a myocardial infarction 6 months before) 6. Known allergic reaction to bevacizumab or MMC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The absolute and qualified surgical success rate of trabeculectomy at 12 months and 24 months defined as intraocular pressure =18 mmHg and >5mmHg with at least 30% reduction in IOP from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Intra- and postoperative complications measured using patient records 2. Additional effects of bevacizumab measured using patient records | — |
Countries
Portugal
Contacts
Public ContactPatrícia José
Outcome results
None listed